Clinical trial · Interventional
Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome
Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk patients. However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH) level post trigger with single injection of GnRH agonist, which might be related to the shorter duration and lower amount of LH induced by GnRH agonist. Our aim is to study dual trigger with GnRH agonist and human chorionic gonadotropin (hCG) for preventing OHSS and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH antagonist protocol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infertility and at High Risk of OHSS | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hCG | Drug | — | UNRESOLVED |
| triptorelin | Drug | Triptorelin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 0.2mg triptorelin and 500 IU hCG
- description
- Patients were triggered with 0.2mg triptorelin and 500 IU hCG
- interventionNames
- Drug: triptorelin
- Drug: hCG
- type
- EXPERIMENTAL
- label
- 0.2mg triptorelin and 1000 IU hCG
- description
- Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
- interventionNames
- Drug: triptorelin
- Drug: hCG
Primary outcomes (4)
- measure
- clinical pregnancy rate per transfer cycle
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * patients with polycystic ovarian syndrome * patients with polycystic ovarian morphology on ultrasound * patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins Exclusion Criteria: * patients undergoing coasting * patients with past ovarian surgery
References
Publications (0)
Data not yet available